NIKKEI 225
27,120.53 +128.32 (+0.48%) HANG SENG
18,087.97 +1,008.46 (+5.90%) CRUDE OIL
88.11 +0.35 (+0.40%) GOLD FUTURES
1,725.10 +4.30 (+0.25%) DOW
30,273.87 -42.45 (-0.14%) BTC-GBP
17,816.99 -177.36 (-0.99%)
AstraZeneca PLC (AZN.L)
| Previous close | 9,958.00 |
| Open | 9,877.00 |
| Bid | 9,947.00 x 0 |
| Ask | 9,949.00 x 0 |
| Day's range | 9,787.00 - 9,979.21 |
| 52-week range | 8,090.32 - 11,540.00 |
| Volume | |
| Avg. volume | 2,323,385 |
| Market cap | 154.082B |
| Beta (5Y monthly) | 0.13 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -58.80 |
| Earnings date | 10 Nov 2022 |
| Forward dividend & yield | 2.22 (2.23%) |
| Ex-dividend date | 11 Aug 2022 |
| 1y target est | 113.08 |
- Fool.co.uk
2 FTSE 100 shares to buy in the UK stock market crash
Following the mini budget, FTSE 100 shares took a beating as the index sank below 7,000. Our writer picks two stocks he'd buy in the market meltdown. The post 2 FTSE 100 shares to buy in the UK stock market crash appeared first on The Motley Fool UK.
- Zacks
Astrazeneca (AZN) Gains But Lags Market: What You Should Know
Astrazeneca (AZN) closed at $55.55 in the latest trading session, marking a +1.29% move from the prior day.
- Business Wire
Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine
WILMINGTON, Del., October 03, 2022--Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive agreement to acquire Lexington, Mass.-based LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company. The proposed acquisition aims to rapidly accelerate Alexion’s growth in genomic medicines through LogicBio’s unique technology, experienced rare disease R&D team, and expertise in pre-clinical development.
